|
1
|
Arrigoni MG, Woolner LB and Bernatz PE:
Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg.
64:413–421. 1972.PubMed/NCBI
|
|
2
|
Travis WD, Linnoila RI, Tsokos MG,
Hitchcock CL, Cutler GB Jr, Nieman L, Chrousos G, Pass H and
Doppman J: Neuroendocrine tumors of the lung with proposed criteria
for large-cell neuroendocrine carcinoma. An ultrastructural,
immunohistochemical, and flow cytometric study of 35 cases. Am J
Surg Pathol. 15:529–553. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Travis W, Colby T, Corrin B, Shimosato Y
and Brambilla E: World health organization international
histological classification of tumours: Histological typing of lung
and pleural tumours. 3rd. Berlin: Springer; 1999
|
|
4
|
Travis W, Brambilla E, Muller-Hermelink H
and Harris C: World health organization classification of
tumoursPathology and genetics: Tumours of the lung, pleura, thymus
and heart. Lyon: IARC; 2004, View Article : Google Scholar
|
|
5
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/American thoracic society/European respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Watanabe R, Ito I, Kenmotsu H, Endo M,
Yamamoto N, Ohde Y, Kondo H, Nakajima T and Kameya T: Large cell
neuroendocrine carcinoma of the lung: Is it possible to diagnose
from biopsy specimens? Jpn J Clin Oncol. 43:294–304. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rossi G, Cavazza A, Marchioni A, Longo L,
Migaldi M, Sartori G, Bigiani N, Schirosi L, Casali C, Morandi U,
et al: Role of chemotherapy and the receptor tyrosine kinases KIT,
PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine
carcinoma of the lung. J Clin Oncol. 23:8774–8785. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Niho S, Kenmotsu H, Sekine I, Ishii G,
Ishikawa Y, Noguchi M, Oshita F, Watanabe S, Nakajima R, Tada H and
Nagai K: Combination chemotherapy with irinotecan and cisplatin for
large-cell neuroendocrine carcinoma of the lung: A multicenter
phase II study. J Thorac Oncol. 8:980–984. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shimada Y, Niho S, Ishii G, Hishida T,
Yoshida J, Nishimura M, Yoh K, Goto K, Ohmatsu H, Ohe Y and Nagai
K: Clinical features of unresectable high-grade lung neuroendocrine
carcinoma diagnosed using biopsy specimens. Lung Cancer.
75:368–373. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
von Pawel J, Jotte R, Spigel DR, O'Brien
ME, Socinski MA, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts
K, et al: Randomized phase III trial of amrubicin versus topotecan
as second-line treatment for patients with small-cell lung cancer.
J Clin Oncol. 32:4012–4019. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Katakami N, Yoshioka H, Okamoto H, Iwamoto
Y, Seto T, Takahashi T, Sunaga N, Kudoh S, Chikamori K, Harada M,
et al: Amrubicin (AMR) versus docetaxel (DTX) as second- or
third-line treatment for non-small cell lung cancer (NSCLC): A
randomized phase III trial. Ann Oncol. 25:(Suppl 4). iv426–iv470.
2014. View Article : Google Scholar
|
|
12
|
Yoshida H, Sekine I, Tsuta K, Horinouchi
H, Nokihara H, Yamamoto N, Kubota K and Tamura T: Amrubicin
monotherapy for patients with previously treated advanced
large-cell neuroendocrine carcinoma of the lung. Jpn J Clin Oncol.
41:897–901. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Onoda S, Masuda N, Seto T, Eguchi K,
Takiguchi Y, Isobe H, Okamoto H, Ogura T, Yokoyama A, Seki N, et
al: Phase II trial of amrubicin for treatment of refractory or
relapsed small-cell lung cancer: Thoracic oncology research group
study 0301. J Clin Oncol. 24:5448–5453. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ettinger DS, Jotte R, Lorigan P, Gupta V,
Garbo L, Alemany C, Conkling P, Spigel DR, Dudek AZ, Shah C, et al:
Phase II study of amrubicin as second-line therapy in patients with
platinum-refractory small-cell lung cancer. J Clin Oncol.
28:2598–2603. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Inoue A, Sugawara S, Yamazaki K, Maemondo
M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, et
al: Randomized phase II trial comparing amrubicin with topotecan in
patients with previously treated small-cell lung cancer: North
Japan lung cancer study group trial 0402. J Clin Oncol.
26:5401–5406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Murakami H, Yamamoto N, Shibata T, Takeda
K, Ichinose Y, Ohe Y, Yamamoto N, Takeda Y, Kudoh S, Atagi S, et
al: A single-arm confirmatory study of amrubicin therapy in
patients with refractory small-cell lung cancer: Japan clinical
oncology group study (JCOG0901). Lung Cancer. 84:67–72. 2014.
View Article : Google Scholar : PubMed/NCBI
|
